nach oben

Reactions Weekly

Erschienen in:

01.06.2019 | Case report

Antineoplastics

Fatal bowel perforation: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Cortellini A, et al. Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice. OncoTargets and Therapy 12: 2159-2170, 25 Mar 2019. Available from: URL: http://doi.org/10.2147/OTT.S194745 - Italy

Titel: Antineoplastics
Fatal bowel perforation: case report
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63586-2

Adverse outcomes with direct-acting antivirals for HCV infections

Clinical study

Posaconazole

Case report

Colchicine

Case report

Cefepime/cefoxitin

Case report

Hyaluronic acid

Case report

Clenbuterol/esmolol/phenylephrine

Case report

Springer Medizin

Antineoplastics

Fatal bowel perforation: case report

Excerpt

Weitere Artikel der Ausgabe 1/2019

Adverse outcomes with direct-acting antivirals for HCV infections

Posaconazole

Colchicine

Cefepime/cefoxitin

Hyaluronic acid

Clenbuterol/esmolol/phenylephrine

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Adverse outcomes with direct-acting antivirals for HCV infections

Posaconazole

Colchicine

Cefepime/cefoxitin

Hyaluronic acid

Clenbuterol/esmolol/phenylephrine